RSLS - Wutah pendapatan taun lumaku ReShape Lifesciences

The success of ReShape Lifesciences (RSLS) relies on the demand for Lap-Band systems and FDA approvals. This chart of sales volume changes compared to last year for the LTM clearly demonstrates the trend, where the metric value is -13.20. ReShape Lifesciences (RSLS) is currently fighting for survival, losing ground due to the expansion of new weight-loss drugs despite developing advanced non-invasive devices for metabolic health.
ReShape Lifesciences, Inc. (RSLS) - rincian metrik lan laporan keuangan

Portfolio managers value the ReShape Lifesciences (RSLS) model for the high margins of its instruments; therefore, analyzing revenue growth rates on a rolling year basis allows for an assessment of cash flow stability under a pessimistic scenario. Year-over-year sales volatility over a rolling 12-month period smooths out random fluctuations, confirming the company's ability to generate free cash flow even during market stagnation.